Pfizer begins study of antiviral pill for prevention of COVID-19

The Pfizer logo is reflected in a drop on a syringe needle in this illustration photo. Pfizer said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection.

The Pfizer logo is reflected in a drop on a syringe needle in this illustration photo. Pfizer said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection. (REUTERS/Dado Ruvic/Illustration)



Estimated read time: 1-2 minutes

WASHINGTON — Pfizer said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.

The drugmaker and its rivals, including U.S.-based Merck and Swiss pharmaceutical Roche, have been racing to develop an easy-to-administer antiviral pill for COVID-19.

The mid-to-late-stage study will test Pfizer's drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.

In the trial, PF-07321332, designed to block the activity of a key enzyme needed for the coronavirus to multiply, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

To date, Gilead Sciences' intravenous drug remdesivir is the only approved antiviral treatment for COVID-19 in the United States.

Pfizer has also started another study of PF-07321332 in non-hospitalized, symptomatic adult patients.

Merck and partner Ridgeback Biotherapeutics recently launched a late-stage trial of their experimental drug molnupiravir for prevention of the COVID-19 infection.

Molnupiravir is also being studied in a late-stage trial in non-hospitalized patients to see if it reduces the risk of hospitalization or death.

Related Stories

Reuters

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast